{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sethi S"],"funding":["European Research Council","NCI NIH HHS"],"pagination":["1123-1136"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6551791"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(6)"],"pubmed_abstract":["<h4>Background</h4>In membranous nephropathy (MN), which is characterized by deposition of immune complexes along the glomerular basement membrane (GBM), phospholipase A2 receptor (PLA2R) and thrombospondin type 1 domain-containing 7A are target antigens in approximately 70% and 1%-5% of cases of primary MN, respectively. In other cases of primary MN and in secondary MN, the target antigens are unknown.<h4>Methods</h4>We studied 224 cases of biopsy-proven PLA2R-negative MN and 102 controls (including 47 cases of PLA2R-associated MN) in pilot and discovery cohorts. We also evaluated 48 cases of PLA2R-negative presumed primary MN and lupus MN in a validation cohort. We used laser microdissection and mass spectrometry to identify new antigens, which were localized by immunohistochemistry.<h4>"],"journal":["Journal of the American Society of Nephrology : JASN"],"pubmed_title":["Exostosin 1/Exostosin 2-Associated Membranous Nephropathy."],"pmcid":["PMC6551791"],"funding_grant_id":["322947","P30 CA015083"],"pubmed_authors":["Specks U","Sethi S","Gross L","Madden BJ","Ronco P","Debiec H","Charlesworth MC","Ravindran A","Hummel AM","Fervenza FC"],"additional_accession":[]},"is_claimable":false,"name":"Exostosin 1/Exostosin 2-Associated Membranous Nephropathy.","description":"<h4>Background</h4>In membranous nephropathy (MN), which is characterized by deposition of immune complexes along the glomerular basement membrane (GBM), phospholipase A2 receptor (PLA2R) and thrombospondin type 1 domain-containing 7A are target antigens in approximately 70% and 1%-5% of cases of primary MN, respectively. In other cases of primary MN and in secondary MN, the target antigens are unknown.<h4>Methods</h4>We studied 224 cases of biopsy-proven PLA2R-negative MN and 102 controls (including 47 cases of PLA2R-associated MN) in pilot and discovery cohorts. We also evaluated 48 cases of PLA2R-negative presumed primary MN and lupus MN in a validation cohort. We used laser microdissection and mass spectrometry to identify new antigens, which were localized by immunohistochemistry.<h4>","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jun","modification":"2025-04-04T07:57:42.484Z","creation":"2025-04-04T07:57:42.484Z"},"accession":"S-EPMC6551791","cross_references":{"pubmed":["31061139"],"doi":["10.1681/asn.2018080852","10.1681/ASN.2018080852"]}}